Du är här


Bionor Pharma ASA: Bionor to host Capital Markets Day in Oslo on 7 October 2015


Bionor to host Capital Markets Day in Oslo on 7 October 2015
(Oslo, Norway, 23 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a
Norwegian biopharmaceutical company focused on developing its proprietary
therapeutic vaccine Vacc-4x for HIV, will host a Capital Markets Day for
institutional and private investors and financial analysts in Oslo on 7
October 2015 at 12:00-15:30 CEST.

Bionor's ChairmanRussell Greig
and CEODavid Solomon
will present the company's strategy, current highlights and next steps for
value creation. Other key personnel from Bionor and Dr.Lars Østergaard
from Aarhus University Hospital will provide information on Bionor's
development plans for Vacc-4x and the REDUC study as well as recent trends in
HIV care and possible pathways towards a functional HIV cure.

To kick off the event, Bionor will host a sandwich lunch with the opportunity
to meet the company's representatives.

Hotel Continental, Stortingsgata 24-26, 0117 Oslo, Norway
7 October 2015
12:00-15:30 CEST


* Meet the Management&sandwich lunch
* Company update - strategy and current highlights
* Understanding HIV - an introduction to the disease
* Functional HIV cure and Bionor's clinical approach
* Anticipated path to market
* Q&A session
* Summary and next steps for value creation.


Please send an email to Lene Larsen atll@bionorpharma.comstating your full
name, company and contact phone number.

Kindly register no later than1 October 2015


The event will also be webcast live, and a replay as well as presentations
will be available on Bionor's website.

Further information

Jørgen F. Ravn, VP Investor Relations&Communications, +45 20 30 39

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on developing
its proprietary therapeutic vaccine,
Vacc-4x, for human immunodeficiency virus (HIV), which, if left untreated,
causes acquired immunodeficiency syndrome, (AIDS), in humans. Bionor Pharma
has first mover potential to advance its therapeutic vaccine, Vacc-4x, in
combination with other medicines, as part of a functional cure for HIV.
Vacc-4x has demonstrated a reduction of viral load in a large, randomized,
controlled Phase II trial, as well as safety and tolerability. Bionor's
current clinical focus is to explore whether Vacc-4x, used with other
medicines as a combination therapy, can reduce the viral load even further,
and the company, through collaboration with Celgene, is investigating Vacc-4x
and the HDAC inhibitor romidepsin in the REDUC study. Bionor is headquartered
in Oslo, Norway, and is listed on the Oslo stock exchange, under the ticker
BIONOR. More information about Bionor is available atwww.bionorpharma.com.

Bionor Capital Markets Day 2015


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.